Who are Atropine/Remifentanil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Belladonna and Opium Suppositories.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atropine-remifentanil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Atropine/Remifentanil — Competitive Intelligence Brief

Atropine/Remifentanil (Atropine/Remifentanil) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic/Opioid combination. Area: Anesthesia.

marketed Anticholinergic/Opioid combination Muscarinic acetylcholine receptor (atropine); mu-opioid receptor (remifentanil) Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Atropine/Remifentanil (Atropine/Remifentanil) — King Saud University. This combination pairs atropine (a muscarinic antagonist) with remifentanil (an opioid agonist) to provide anticholinergic and analgesic/sedative effects during anesthesia.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atropine/Remifentanil TARGET	Atropine/Remifentanil	King Saud University	marketed	Anticholinergic/Opioid combination	Muscarinic acetylcholine receptor (atropine); mu-opioid receptor (remifentanil)
Belladonna and Opium Suppositories	Belladonna and Opium Suppositories	Kristina A. Butler	marketed	Anticholinergic/opioid combination	Muscarinic acetylcholine receptors; mu opioid receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic/Opioid combination class)

King Saud University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atropine/Remifentanil — Competitive Intelligence Brief. https://druglandscape.com/ci/atropine-remifentanil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab